Sodium‐glucose cotransporter 2 (SGLT2) inhibitors gained universal prominence across the cardiac community and recently became incorporated into guidelines as a treatment of choice for heart failure with reduced ejection fraction (HFrEF), after their use as antidiabetic drugs for many years.1, 2. Here, SLC5A2 is linked to heart failure.